study, to determine the metastasis-related genes of gastric cancer, we analyzed the differential gene expression of established human gastric cancer cell lines -AZH5c, a highly liver metastatic cell line; AZ-P7a, a cell line with high peritoneal dissemination; AZ-L5G, a highly lymph node metastatic cell line -and compared the fi ndings with those from AZ-521, a parental low metastatic cell line. The results revealed that the ET-A gene was the only one of three highly metastatic cell lines that was generally up-regulated, in contrast to the AZ-521 line. Thus, we evaluated the possibility that ET-A might play an important role in the mechanism of gastric cancer metastasis and that the ET-A blockade could have an antimetastatic effect. We conducted in vitro and in vivo experiments using a non-peptideselective ET-A antagonist, YM598 (Astellas Pharma, Tokyo, Japan). The present study demonstrates the inhibitory effect of ET-A blockade on the cell proliferation, tumor growth, and liver metastasis of gastric cancer.
Introduction
Gastric cancer is the main cause of cancer death in Japan. In particular, more effi cacious treatment modalities are needed for metastatic gastric cancer. In this Tokyo, Japan), and established highly metastatic variants, AZ-H5c (a liver metastatic line), AZ-P7a (a peritoneal dissemination line), and AZ-L5G (a lymph node metastatic line), were used in this study [1] [2] [3] . These three highly metastatic variants were established in our institution as previously described [1] [2] [3] ; their metastatic rates are presented in Fig. 1 . The cell lines were maintained in a humidifi ed atmosphere of 95% air and 5% CO 2 at 37 °C by culturing in an RPMI 1640 medium (Asahi Techno Glass, Funabashi, Japan) supplemented with 10% fetal bovine serum (FBS) (GIBCO, Grand Island, NY, USA), tylosin tartrate 8 µg/ml (SigmaAldrich, St. Louis, MO, USA), penicillin 50 units/ml, and streptomycin 50 mg/ml (GIBCO). The cells were passaged and expanded by trypsinization of cell monolayers followed by replating every 4-5 days. The culture medium was changed every 2-3 days.
Target preparation
Differential gene expression among the four cell lines was measured. First, poly(A)
+ mRNA was extracted from cultured cell pellets using a Fast Track mRNA Isolation Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions and quantifi ed spectrophotometrically. Double-stranded cDNA was synthesized from purifi ed poly(A)
+ mRNA using the T7-(dt) 24 primer (5′-GGCCAGTGAATTGTAAGTA ATACGACTCACTATAGGGAGGCGG-(dt) 24 -3′) and a Superscript Kit (Invitrogen). Double-stranded cDNA was purifi ed by phenol/chloroform extraction with phase lock gels. Biotin-labeled antisense cRNA (target) in an in vitro transcription reaction (IVT) was produced using the ENZO BioArray RNA Transcript Labeling Kit (Affymetrix, Santa Clara, CA, USA). The IVT product (cRNA) was then cleaned up using QIAGEN RNeasy Columns (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Subsequently, the cRNA was fragmented for target preparation.
Target hybridization and washing, staining, and scanning probe arrays
A hybridization cocktail was prepared using a Gene Chip eukaryotic Hybridization Control Kit (Affymetrix). The cocktail was then hybridized on the Gene Chip Human Cancer G110 Array (Affymetrix) during a 16-h incubation in a 45 °C oven. Before hybridization to the G110 array, the target RNA quality was determined by hybridization to the Affymetrix Test 2 Array.
Immediately following hybridization, the hybridized probe array was subjected to an automated washing and staining protocol on the fl uid station according to the Gene Chip Fluidics Station 400 User's Manual. Each probe array was scanned twice. The computer workstation automatically overlaid the twice-scanned images and averaged the intensities of each probe cell for the greatest assay sensitivity.
Array data analysis
Data were analyzed using Microarray Suite 4.0 software (Affymetrix). The software calculated the average intensity of the signals from each probe array and then applied the selected array algorithm to determine the expression levels for each gene. The average expression level of each gene in each cell line was calculated, and the ratio of the average expression level between the two cell lines was then calculated. Comparative analysis of the parental cell line, metastatic cell lines, and each metastatic cell line was performed. The cutoff value was set at 3.0 for the ratio.
Detection of mRNAs by RT-PCR
Total RNA was extracted from the four cell lines with the QIAGEN RNeasy Mini Kit according to the manufacturer's instructions. All RNA samples were quantifi ed by spectrophotometry and stored at −80 °C until processed for reverse transcription (RT). First-strand cDNA was synthesized from 1 µg of the total RNA using the Super Script Choice System for cDNA Synthesis in 19 µl of reaction volume, according to the instructions To evaluate the metastatic potential, cultured cells from each cell line were inoculated into the spleen (AZ-H5c, 5 × 10 6 cells), peritoneal cavity (AZ-p7a, 1 × 10 7 cells), and perigastric wall (AZ-L5G, 5 × 10 6 cells) of nude mice. Three weeks after inoculation, the mice were sacrifi ced and examined for metastasis. The three established cell lines demonstrated signifi cantly higher metastatic ability than the parental AZ-521 cells. The liver metastatic rate of AZ-H5c was 81%; the peritoneal dissemination rate of AZ-P7a was 80%; and the lymph node metastatic rate of AZ-L5G was 85%. In contrast, the metastatic rates of AZ-521 were 14% for the liver, 14% for the peritoneal cavity, and 33.3% for the lymph nodes. *P < 0.001 versus control provided. The synthesized fi rst-strand cDNA was amplifi ed by the polymerase chain reaction (PCR) in a fi nal reaction volume of 50 µl, containing 1 µl of cDNA, 0.5 µM of each oligonucleotide primer, 0.2 mM of each dNTP, 2.5 units of Taq DNA polymerase, and 5 µl of a 10 × PCR buffer. The sequences of primers used were (sense) 5′-TTT GCC TCA AGA TGG AAA CC-3′ and (antisense) 5′-TGT GGG CAA TAG TTG TGC AT-3′ for ET-A (223 bp); and (sense) 5′-GAG TCA ACG GAT TTG GTC GT-3′ and (antisense) 5′-TTG ATT TTG GAG GGA TCT CG-3′ for GAPDH (238 bp). Amplifi cation was carried out in a Gene Amp PCR system 9700 (Applied Biosystems, Foster City, CA, USA), and the PCR conditions were as follows: 94 °C, 5 min for 1 cycle; 94 °C for 30 s (denaturation), 55 °C for 30 s (annealing), and 72 °C for 30 s (extension) for 25 cycles followed by 7 min fi nal extension at 72 °C. The amplifi cation products were electrophoresed on 1.0% (w/v) agarose gels and visualized by ethidium bromide staining under ultraviolet light.
Cell proliferation assay in vitro
AZ-521 and AZ-H5c cultured in an RPMI 1640 medium were harvested at 80% confl uence and seeded at a plating density of 5 × 10 5 cells/well in six-well plates. They were then cultured for 24 h, and the culture medium was changed to an FBS-free medium supplemented with YM598. We studied seven concentrations of YM598 from 0 to 0.2 mM. Following culture with YM598 for 48 h, the cells were dispersed by trypsinization and counted in a hemocytometer. The experiments were performed in triplicate and repeated twice.
Assay of tumor growth in vivo
Five-week-old female (nu/nu) mice were given injections subcutaneously (s.c.) in the back with 1 × 10 7 AZH5c cells suspended in 100 µl of PBS. The mice were then randomly divided into four groups of eight animals each and received the following treatments: group 1 was injected intraperitoneally (i.p.) with 100 µl of PBS every day for 3 weeks after inoculation; group 2 was injected in the same way with a solution containing 0.01 mg of YM598 dissolved in PBS at a dose of 0.5 mg/kg; group 3 was injected in the same way with a solution containing 0.02 mg of YM598 dissolved in PBS at a dose of 1 mg/kg; and group 4 was injected in the same way with a solution containing 0.2 mg of YM598 dissolved in PBS at a dose of 10 mg/kg. These doses were chosen according to the supplier's recommendations [4] . Treatment started on the same date of the inoculation. Tumor volume was measured with a caliper and calculated as (length × width × height)/2. Mouse body weight was measured once a week.
Assay of liver metastasis in vivo
Five-week-old female (nu/nu) mice were given injections of 5 × 10 6 AZ-H5c cells suspended in 100 µl of PBS in the spleen. The mice were then randomly divided into four groups of fi ve or six animals each and received the following treatments: group 1 was injected with 100 µl of PBS i.p. every 2 days for 3 weeks after inoculation; group 2 was injected with YM598 every 2 days for 3 weeks after inoculation at a dose of 1 mg/kg i.p.; group 3 was injected with YM598 in the same way at a dose of 10 mg/kg; and group 4 was injected with YM598 at a dose of 1 mg/kg starting 2 days before inoculation. The mice were sacrifi ced 3 weeks later, and the liver metastasis rate was calculated.
Statistical analysis
The statistical difference was determined by Student's t-test. P < 0.05 was considered signifi cant.
Results

Microarray assay
A differential gene expression analysis using a DNA microarray demonstrated that many genes were up-and down-regulated in highly metastatic cell lines, in contrast to the parental cell line AZ-521. In these differentially expressed genes, the ET-A gene was the only one of three highly metastatic variants that was generally up-regulated, in contrast to the AZ-521 line. The ratios of the ET-A mRNA expression level in comparison with AZ-521 were 30.1 (AZ-H5c), 57.3 (AZ-P7a), and 47.8 (AZ-L5G) ( Table 1) .
Detection of mRNAs by RT-PCR
RT-PCR revealed that the mRNA expression of ET-A in AZ-H5c, AZ-p7a, and AZ-L5G was higher than that of the low metastatic AZ-521. The ET-A mRNA upregulation in AZ-H5c, AZ-p7a, and AZ-L5G was confi rmed (Fig. 2) .
Effect of YM598 on AZ-521 and AZ-H5c cell proliferation in vitro
After a 48-h incubation with YM598 in the 0.01-0.05 mM concentration, the number of viable cells of AZ-521 and AZ-H5c decreased. In the 0.1-0.2 mM concentrations of YM598, only a few viable cells were seen in the two lines. There was no signifi cant difference between the two lines (Fig. 3) . These data suggest that YM598 may have a growth inhibition effect in the 0.01-0.05 mM concentrations on both lines in vitro. In contrast, the cyto-toxicity of YM598 was shown in the 0.1-0.2 mM concentrations.
Effect of YM598 on the tumor growth of AZ-H5c cells in vivo
As shown in Fig. 4 , the administration of YM598 inhibited growth of the AZ-H5c tumors signifi cantly at any dosage. The mean tumor volumes at autopsy were 1453.9 mm 3 (group 1), 502.7 mm 3 (group 2), 448.0 mm 3 (group 3), and 293.7 mm 3 (group 4). The growth inhibition rates, compared with that of group 1, were 34.6% (group 2), 30.8% (group 3), and 20.2% (group 4). There was no evidence of gross toxicity, such as weight loss, resulting from YM598 treatment; and no death occurred during the experiment in any of the groups (Fig. 5) .
Effect of YM598 on the liver metastasis of AZ-H5c cells in vivo
In the control group, fi ve of six mice (metastatic rate 83.3%) developed liver metastasis. On the other hand, (Fig. 6) . These results demonstrated that YM598 administration signifi cantly reduced the liver metastatic rate of AZ-H5c. No advantage was obtained from dose escalation or pretreatment with YM598.
Discussion
With metastatic progression, gastric cancer is incurable, and existing systemic therapies are largely ineffective. Thus, the development of novel therapeutic strategies is needed. Differential gene expression analysis using a DNA microarray is useful for selecting a candidate gene for cancer therapy. To select the metastasis-related genes of gastric cancer, we performed a microarray analysis of three highly metastatic gastric cancer cell lines and compared the results with those from a low metastatic parental cell line. The results suggested that the ET-A gene plays an important role in gastric cancer metastasis.
The family of ETs, including ET-1, ET-2, and ET-3, consists of 21 amino acids that mediate a variety of physiological functions. The effects of ETs on mammalian cells are mediated by two distinct subtypes of G protein-coupled receptors: ET-A, which binds ET-1 and ET-2 with high affi nity and ET-3 with low affi nity; and ET-B, which binds all ET isopeptides with equal affi nity [5] . Several human cancer cell lines produce ET-1, which has autocrine/paracrine growth factor functions [6, 7] . Elevated plasma levels of ET-1 have also been detected in patients with various solid tumors, including hepatocellular [8] and colorectal [9] cancers. Furthermore, increased ET-A expression in malignant tissue has been demonstrated in several cancer types, including breast [10] , ovarian [11] , and advanced prostate [12] cancer. The engagement of ET-A by ET-1 is known to trigger activation of tumor growth [13] , VEGF-induced angiogenesis [11] , cancer cell invasiveness [14] , and inhibition of apoptosis [15] . However, little is known regarding how the ET family is involved in cancer metastasis.
In this study, we investigated the effects of ET-A blockade on cell proliferation, tumor growth, and liver metastasis of a highly liver metastatic cell line, AZ-H5c. We used a non-peptide-selective ET-A antagonist, YM598, for the ET-A blockade. It is orally active and has high affi nity and selectivity for ET-A with a long duration of action [4] . To date, the effects of the ET-A blockade on gastric cancer have not been investigated. The in vivo study demonstrated that YM598 had a signifi cant growth inhibition effect on AZ-H5c at a dosage of 0.5-10.0 mg/kg. YM598 also decreased the liver metastatic rate of AZ-H5c at 1 mg/kg; however, no advantage was obtained from dose escalation or pretreatment. These results suggested that the liver metastasisinhibiting effect of YM598 could be largely achieved by growth inhibition of AZ-H5c. The mechanism through which ET-1 contributes to cell growth is thought to be as follows: Binding of ET-1 to ET-A in the plasma membrane triggers signal-transduction pathways through Gq, a pertussis toxin-intensive G protein that is coupled to the ET-A intracellular domain. Activation of phospholipase C, protein tyrosine kinases, and RAS ultimately results in activation of the RAF/MEK/MAPK pathway. Translocation of intracellular calcium (Ca 2+ ) and activation of protein kinase C and activated MAPK induce nuclear transcription of proto-oncogenes (e.g., c-FOS, c-JUN, and c-MYC), leading to cell growth and mitogenesis [16] . Furthermore, ET-1 not only promotes cell growth, it suppresses apoptosis of cancer cells [15, 17] . Therefore, ET-A antagonists could have the effects of both growth inhibition and apoptosis induction on carcinoma xenografts.
Tumor growth is one of multiple steps in a cancer metastatic pathway, and metastasis may possibly be inhibited by blocking one of these steps. In this study, YM598 markedly decreased liver metastasis, which might be due mainly to tumor growth inhibition. However, any other additional effect of the ET-A blockade (e.g., inhibition of cancer cell invasiveness or angiogenesis) could also contribute to reduction of the metastatic rate. Further studies are needed to defi ne the defi nitive role of the ET-A system in gastric cancer metastasis. Considering its clinical usefulness, it should be determined if YM598 has additional antitumor effects in combination with chemotherapy or radiation therapy.
Conclusion
The present study demonstrated that ET-A blockade by YM598, a non-peptide-selective ET-A antagonist, is effective in inhibiting tumor growth and liver metastasis of a gastric cancer cell line in vivo. Further studies to assess the mechanisms of the effect and the clinical impact of ET-A blockade in gastric cancer are needed. These results suggest that ET-A blockade by YM598 could be a novel therapeutic strategy for inhibiting gastric cancer growth and metastasis.
